An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Karuna Therapeutics (NASDAQ: KRTX), a clinical-stage biopharmaceutical company, announced that Andrew Miller, Ph.D., its COO, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 8:00 a.m. ET. A live webcast of the presentation will be available on the Investor Relations page of Karuna's website, with a replay archived for 30 days post-conference. Karuna is focused on developing transformational medicines for psychiatric and neurological conditions, leveraging neuroscience to create effective treatments for patients.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., founder and chief operating officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 8:00 a.m. ET.
A live webcast of the presentation will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 30 days on Karuna’s website following the conference.
About Karuna
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.
